OGT presents prostate cancer data at the CHI Early Oncology Partnering Showcase...

OGT presents prostate cancer data at the CHI Early Oncology Partnering Showcase and Tri-Con 2011

Oxford, UK – 23 February 2011. Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine , is discussing recent developments in biomarker discovery at this year’s CHI International Molecular Medicine Tri-Conference (Tri-Con) in San Francisco, USA (23-25 th February). As well as presenting its genomic and proteomic diagnostic biomarker services at Tri-Con booth 626, OGT gave a talk at the CHI Early Oncology Partnering Showcase immediately before the Tri-Con event. The talk, entitled “Development of a panel of biomarkers for improved detection of prostate cancer”, was presented by OGT’s head of Business Development Biomarker Discovery, Will Colón. It described the use of OGT’s unique “functional protein” array platform to identify a panel of autoantibody biomarkers that can detect prostate cancer with greater sensitivity and specificity than current tests. OGT has also produced a new brochure outlining the benefits of its diagnostic biomarker technology, which is available at the OGT booth (# 626), together with OGT representatives, who are on hand for more in-depth discussion.

OGT’s presentation at the CHI Early Oncology Partnering Showcase and its new diagnostic biomarker brochure are available to view at www.ogt.co.uk/tricon.asp .

For further information, please contact:

Oxford Gene Technology, Begbroke Science Park , Sandy Lane , Yarnton, Oxford OX5 1PF
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: products @ogt.co.uk

W: www.ogt.co.uk